Peregrine Capital Management LLC Purchases 54,100 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Peregrine Capital Management LLC lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 18.1% in the fourth quarter, HoldingsChannel reports. The fund owned 352,205 shares of the medical equipment provider’s stock after acquiring an additional 54,100 shares during the period. Peregrine Capital Management LLC’s holdings in BioLife Solutions were worth $9,143,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. D.A. Davidson & CO. lifted its holdings in BioLife Solutions by 1.3% in the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after purchasing an additional 519 shares in the last quarter. Stifel Financial Corp raised its holdings in BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 670 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in BioLife Solutions during the 3rd quarter valued at $28,000. Curi RMB Capital LLC grew its position in BioLife Solutions by 0.5% in the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after acquiring an additional 2,283 shares during the last quarter. Finally, Quest Partners LLC bought a new position in BioLife Solutions in the 3rd quarter valued at $57,000. 93.24% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. This represents a 2.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now directly owns 121,779 shares in the company, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,678 shares of company stock worth $317,990. 2.20% of the stock is owned by corporate insiders.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $27.77 on Tuesday. BioLife Solutions, Inc. has a one year low of $14.50 and a one year high of $29.55. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -26.20 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The business’s 50 day moving average price is $26.84 and its 200 day moving average price is $25.37.

Wall Street Analyst Weigh In

BLFS has been the topic of several research analyst reports. KeyCorp upped their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. HC Wainwright reduced their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.